Venofer Shortage Update: What Patients Need to Know in 2026

For patients with chronic kidney disease (CKD) who rely on Venofer (iron sucrose injection) to treat iron deficiency anemia, the 2024 supply shortage was a stressful reminder of how fragile access to specialty IV medications can be. If you've been searching for the latest shortage status, this post covers what happened, where things stand now in 2026, and the steps you can take to protect your treatment access going forward.

Current Status: Is Venofer in Shortage in 2026?

As of 2026, Venofer is not in a nationwide shortage. The allocation period — which ran from June 2024 through November 2024 — has ended, and American Regent has restored normal supply levels. Venofer has been on the market since 2000 and, prior to 2024, had been consistently available throughout its 25-year history.

That said, localized supply gaps can still occur at the facility level. If your dialysis center or infusion clinic says Venofer is unavailable, the issue is most likely specific to their distributor relationship or ordering cycle — not a national shortage.

What Happened During the 2024 Shortage?

In June 2024, American Regent placed Venofer on allocation — meaning each facility was limited in how much product it could order per week. According to the manufacturer, product was continuing to ship weekly throughout the allocation period, but the constrained quantities created real-world shortfalls at many dialysis centers and infusion clinics.

Dialysis facilities that serve large patient populations on fixed hemodialysis schedules were hit hardest. Unlike outpatient infusion patients, hemodialysis patients are typically tied to a specific facility and cannot easily receive treatment elsewhere. Delayed iron therapy in these patients can worsen anemia and compromise the effectiveness of ESA therapy.

By November 2024, the allocation was lifted and supply levels returned to normal. American Regent's statement emphasized that Venofer had been available throughout the allocation period, just in limited quantities per order.

Why Did the 2024 Shortage Happen?

The exact cause of the 2024 Venofer allocation was not publicly detailed by American Regent, but common drivers of IV iron supply disruptions include:

Manufacturing constraints: Venofer is an aqueous iron-sucrose complex that requires sterile manufacturing under tight quality controls. Equipment maintenance, validation activities, or regulatory inspection responses can temporarily reduce output.

Supply chain dependencies: Venofer is manufactured under license from Vifor International in Switzerland. International manufacturing and shipping add complexity and potential points of failure in the supply chain.

Sustained and growing demand: The CKD patient population continues to grow in the United States. More patients requiring regular IV iron therapy increases baseline demand, leaving less buffer capacity when production is constrained.

How to Monitor Venofer Shortage Status

Patients can monitor the official FDA Drug Shortage Database at accessdata.fda.gov/scripts/drugshortages for real-time shortage listings. If Venofer appears there, it means the FDA has been officially notified of a supply disruption. During the 2024 allocation period, patients and providers also received updates directly from American Regent through their distribution channels.

You can also sign up to receive shortage notifications from the American Society of Health-System Pharmacists (ASHP), which publishes one of the most comprehensive drug shortage databases in the country at ashp.org/drug-shortages.

39,483+ patients found their medications in stock

39K+

Find Venofer In Stock Today →

What Patients Should Do Now

Even though Venofer supply is currently normal, the 2024 shortage was a reminder that access to IV iron medications can be disrupted without warning. Here are proactive steps CKD patients can take:

Track your iron labs: Know your latest serum ferritin and transferrin saturation (TSAT). If you know your iron stores are low, you can communicate urgency to your care team more effectively.

Ask your provider about a contingency plan: Before a shortage hits, ask your nephrologist which IV iron alternative they would prescribe and whether your insurance pre-authorizes it.

Confirm stock before each appointment: A quick call to your infusion center before your scheduled treatment can prevent a wasted trip.

Use medfinder: If your clinic is out, medfinder can call providers near you to find which ones have Venofer or iron sucrose in stock. Visit medfinder.com to learn more.

Key Takeaways

Venofer is NOT in nationwide shortage as of 2026

The 2024 allocation (June–November 2024) has been resolved

Local supply gaps can still occur at individual facilities

Generic iron sucrose and other IV iron products are available alternatives

Read our full guide to Venofer alternatives if your clinic is currently out of stock